فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 160 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 320 mikrog / 9 mikrog / inhalaatio - formoteroli ja budesonidi

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

chiesi farmaceutici s.p.a - beclometasone dipropionate, formoterol fumarate dihydrate - inhalaatiojauhe - 100 mikrog / 6 mikrog / inhalaatio - formoteroli ja beklometasoni

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

astrazeneca oy - budesonide, formoterol fumarate dihydrate - inhalaatiosumute, suspensio - 160 mikrog / 4.5 mikrog / inhalaatio - formoteroli ja budesonidi

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

orion corporation - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - 80 mikrog / 4.5 mikrog / inhalaatio - formoteroli ja budesonidi

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 80 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

mundipharma oy - fluticasoni propionas,formoteroli fumaras dihydricus - inhalaatiosumute, suspensio - 125 mikrog / 5 mikrog / annos - formoteroli ja flutikasoni

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

astrazeneca oy - budesonide, formoterol fumarate dihydrate - inhalaatiosumute, suspensio - 80 mikrog / 2.25 mikrog / inhalaatio - formoteroli ja budesonidi

الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).